Hai Duong Pharmaceutical Medical Material Joint Stock Co
UUPCOM:DHD26,700.00
VND
0.00
(0.00%)
ISIN
VN000000DHD7
Return %
Stock
S&P 500
1Y
-13.87
14.20
3Y
43.29
81.12
5Y
45.72
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hai Duong Vietnam
- IPO Date
- May 5, 2017
- Website
- hdpharma.vn
- Similar Companies
- Business
- Hai Duong Pharmaceutical Medical Material Joint Stock Company (HDPHARMA) is a Vietnam-based pharmaceutical manufacturer and distributor specializing in the research, development, production, and commercialization of modern pharmaceuticals, traditional herbal medicines, health supplements, and medical supplies. The company operates across ethical (ETC) and over-the-counter (OTC) healthcare segments, providing an extensive portfolio of products that includes antibiotics, notably cephalosporins, beta-lactams, and macrolides; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; cardiovascular, metabolic, and gastrointestinal medications; respiratory, cough, and anti-allergic treatments; central nervous system and multivitamin formulations; traditional herbal remedies and oriental medicinal extracts; dietary and nutritional supplements; and medical consumables and healthcare materials. HDPHARMA produces finished pharmaceuticals in diverse delivery formats, including film-coated tablets, hard and soft capsules, effervescent tablets, dry syrups, oral solutions, granules, powders, topical creams, and sterile injectables. The company distributes its products across Vietnam through public and private hospital systems, clinic networks, and wholesale and retail pharmacy chains, while also exporting selected product lines to international markets across Southeast Asia and neighboring regions. In recent operational developments, HDPHARMA has significantly upgraded and expanded its high-tech pharmaceutical manufacturing infrastructure in Hai Duong to meet rigorous EU-GMP standards alongside WHO-GMP certifications, substantially improving its qualification and competitive positioning in higher-tier hospital drug bidding groups. The company has also broadened its strategic contract manufacturing (OEM/ODM) and technology transfer partnerships with domestic and multinational pharmaceutical enterprises, accelerated the development of high-potency solid dosage forms and standardized botanical extracts, and upgraded its supply chain and digital enterprise resource systems to strengthen domestic retail distribution channels. Founded in 1961, Hai Duong Pharmaceutical Medical Material Joint Stock Company is headquartered in Hai Duong City, Hai Duong Province, Vietnam, and is listed on the UPCoM market of the Hanoi Stock Exchange under the ticker symbol DHD.